Narox (Etoricoxib)

Etoricoxib works by selectively blocking the cyclooxygenase‑2 (COX‑2) enzyme, which is essential for the production of prostaglandins that cause inflammation, pain, and fever. By inhibiting COX‑2 while sparing COX‑1, it reduces inflammatory mediators at the site of disease with a lower risk of gastrointestinal irritation compared with non‑selective NSAIDs.

The appropriate dose of Narox is determined by the prescribing healthcare professional based on the patient’s specific condition, severity, and overall health status. Dosage may be adjusted for efficacy and tolerability, and patients should follow the prescriber’s instructions without self‑adjusting the regimen.

Safety data for Etoricoxib in pregnancy and lactation are limited, and the drug is generally not recommended for use in pregnant or breastfeeding women unless clearly needed and prescribed by a qualified clinician. The potential risks to the fetus or infant should be weighed against the therapeutic benefits.

To order Narox, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including any cold‑chain requirements), and assist with import documentation.

Narox (Etoricoxib) is a selective COX‑2 inhibitor, offering anti‑inflammatory and analgesic effects similar to traditional NSAIDs but with reduced gastrointestinal irritation because COX‑1 is spared. However, it may carry a higher cardiovascular risk profile compared with some non‑selective NSAIDs, so clinicians balance efficacy, safety, and patient risk factors when choosing therapy.

Narox should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in bathrooms or other humid environments.

Narox is taken orally, usually with a full glass of water. It can be taken with or without food, but patients should follow the prescribing clinician’s guidance regarding timing relative to meals to minimize potential stomach discomfort.

Serious risks associated with Narox include cardiovascular events such as heart attack or stroke, severe gastrointestinal bleeding or ulceration, renal impairment, and rare but life‑threatening skin reactions like Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience chest pain, sudden weakness, severe abdominal pain, blood in stool, or skin rash.

Narox should be avoided in individuals with known hypersensitivity to Etoricoxib or other COX‑2 inhibitors, those with a history of cardiovascular disease (e.g., myocardial infarction, stroke), uncontrolled hypertension, severe liver or kidney impairment, and in patients who are currently taking anticoagulants, other NSAIDs, or medications that may increase bleeding risk unless closely monitored.